Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference

About this update from Bionano Genomics, Inc.

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27 th Annual Global Investment Conference on Monday, September 8 th , 2025. Conference & Webcast Details A replay / recording of the session will be available following the conference through the Bionano website at  ir.bionano.com  for at least 30 days. About Bionano Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit  www.bionano.com  or  www.bionanolaboratories.com . Bionano’s products are for research use only and not for use in diagnostic procedures. Contacts Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 [email protected] Investor Relations: Kelly Gura Gilmartin Group +1 (212) 229-6163 [email protected]

View stock analysis, news, and events for Bionano Genomics, Inc.